Louisiana State Employees Retirement System Makes New Investment in Elanco Animal Health Incorporated $ELAN

Louisiana State Employees Retirement System purchased a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 138,300 shares of the company’s stock, valued at approximately $2,785,000.

Several other large investors have also made changes to their positions in ELAN. AQR Capital Management LLC raised its position in Elanco Animal Health by 116.4% during the first quarter. AQR Capital Management LLC now owns 524,507 shares of the company’s stock valued at $5,332,000 after acquiring an additional 282,081 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Elanco Animal Health during the 1st quarter worth $2,065,000. Goldman Sachs Group Inc. raised its holdings in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares in the last quarter. Empowered Funds LLC lifted its stake in shares of Elanco Animal Health by 35.2% in the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after purchasing an additional 4,121 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock valued at $18,830,000 after purchasing an additional 76,408 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on ELAN shares. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 3rd. Zacks Research lowered Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. UBS Group raised their price objective on Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Barclays started coverage on Elanco Animal Health in a research report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 target price for the company. Finally, KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus target price of $23.78.

Insider Activity at Elanco Animal Health

In related news, CFO Robert M. Vanhimbergen bought 6,950 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the completion of the purchase, the chief financial officer owned 124,233 shares in the company, valued at approximately $2,688,402.12. This represents a 5.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Lawrence Erik Kurzius bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were purchased at an average cost of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the transaction, the director owned 131,773 shares of the company’s stock, valued at $2,806,764.90. This represents a 8.21% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 43,450 shares of company stock worth $937,883 over the last ninety days. Corporate insiders own 0.89% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN opened at $23.47 on Friday. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $23.89. The company has a market cap of $11.66 billion, a P/E ratio of 391.20, a P/E/G ratio of 3.23 and a beta of 1.87. The business’s 50 day moving average is $22.27 and its two-hundred day moving average is $19.28. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter last year, the company posted $0.13 earnings per share. Elanco Animal Health’s quarterly revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, equities analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.